18F-FDG uptake in squamous cell carcinoma of the cervix is correlated with glucose transporter 1 expression

Journal of Nuclear Medicine

Volumn 45, Issue 1, 2004, Pages 22-29

  Yen, Tzu Chen ^a   See, Lai Chu ^a   Lai, Chyong Huey ^a   Chou, Wu Yah Huei ^a   Ng, Koon Kwan ^a   Ma, Shih Ya ^a   Lin, Wuu Jyh ^b   Chen, Jenn Tzong ^b   Chen, Wen Jie ^a   Lai, Chiung Ru ^c   Hsueh, Swei ^a,d  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b INSTITUTE OF NUCLEAR ENERGY RESEARCH   (Taiwan)

^c TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^d CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Cervical cancer; Glucose transporter 1; Squamous cell carcinoma

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GLUCOSE TRANSPORTER 1; DIAGNOSTIC AGENT; GLUCOSE TRANSPORTER; RADIOPHARMACEUTICAL AGENT; SLC2A1 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; TUMOR VOLUME; UTERINE CERVIX BIOPSY; UTERINE CERVIX CARCINOMA; CLINICAL TRIAL; FEMALE; METABOLISM; MIDDLE AGED; PATHOLOGY; REPRODUCIBILITY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; STATISTICS; TUMOR RECURRENCE; UTERINE CERVIX TUMOR;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; FEMALE; FLUORODEOXYGLUCOSE F18; GLUCOSE TRANSPORTER TYPE 1; HUMANS; MIDDLE AGED; MONOSACCHARIDE TRANSPORT PROTEINS; NEOPLASM RECURRENCE, LOCAL; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; STATISTICS; UTERINE CERVICAL NEOPLASMS;

EID: 1842503945     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Isselbacher KJ. Sugar and amino acid transporter by cells in culture: differences between normal and malignant cells. N Engl J Med. 1972;286:929-933.
2. 18F]fluoro-D-glucose in liver metastases from colon cancer. J Nucl Med. 1982;23:1133-1137.
3. Minn H, Joensuu H, Ahonen A, Klemi P. Fluorodeoxyglucose imaging: a method to assess the proliferative activity of human carcinoma in vivo - comparison with DNA flow cytometry in head and neck tumors. Cancer. 1988;61:1776-1781.
4. Filer JS, Mueckler MM, Usher P, Lodish HF. Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes. Science. 1987;235:1492-1495.
5. Mueckler M. Facilitative glucose transporters. Eur J Biochem. 1994;219:713-725.
6. Pessin JE, Bell GI. Mammalian facilitative glucose transporter family: structure and molecular regulation. Ann Rev Physiol. 1992;54:911-930.
7. 18fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol. 2002;20:379-387.
8. Noguchi Y, Saito A, Miyagi Y, et al. Suppression of facilitative glucose transporter 1 mRNA can suppress tumor growth. Cancer Lett. 2000;154:175-182.
9. Kawamura T, Kusakabe T, Sugino T, et al. Expression of glucose transporter-1 in human gastric cancer: association with tumor aggressiveness, metastasis, and patient survival. Cancer. 2001;92:634-641.
10. 18F-FDG PET, and hexokinase-II and glucose transporter-1 expression in pancreatic cancer. J Nucl Med. 2002;43:173-180.
11. 18F] FDG uptake in non-small cell lung cancer. Eur J Nucl Med. 2000;27:1778-1785.
12. 18F-fluoro-2-deoxyglucose positron emission tomography in the evaluation of recurrent ICC. Anticancer Res. 2001;21:2957-2961.
13. Grigsby PW, Siegel BA, Dehdashti F. Lymph node staging by positron emission tomography in patients with carcinoma of the cervix. J Clin Oncol. 2001;19:3745-3749.
14. Reinhardt MJ, Ehritt-Braun C, Vogelgesang D, et al. Metastatic lymph nodes in patients with ICC: detection with MR imaging and FDG PET. Radiology. 2001;218:776-782.
15. Rose PG, Adler LP, Rodriguez M, Faulhaber PF, Abdul-Karim FW, Miraldi F. Positron emission tomography for evaluating para-aortic nodal metastasis in locally advanced cervical cancer before surgical staging: a surgicopathologic study. J Clin Oncol. 1999;17:41-45.
16. Yen TC, Ng KK, Ma SY, et al. Value of dual-phase 2-fluoro-2-deoxy-D- glucose positron emission tomography in cervical cancer [abstract]. J Nucl Med. 2003;44(suppl):390P.
17. Hustinx R, Smith RJ, Benard F, et al. Dual time point fluorine-18 fluorodeoxyglucose positron emission tomography: a potential method to differentiate malignancy from inflammation and normal tissue in the head and neck. Eur J Nucl Med. 1999;26:1345-1348.
18. Airley R, Loncaster J, Davidson S, et al. Glucose transporter Glut1 expression correlates with tumor hypoxia and predicts metastasis-free survival in advanced cancer of the cervix. Clin Cancer Res. 2001;7:928-934.
19. Brown RS, Leung JY, Kison PV, Zasadny KR, Flint A, Wahl RL. Glucose transporters and FDG uptake in untreated primary human non-small cell lung cancer. J Nucl Med. 1999;40:556-565.
20. Yen TC, Ng KK, Ma SY, et al. Value of dual-phase 2-fluoro-2-deoxy-D- glucose positron emission tomography in cervical cancer. J Clin Oncol. 2003;21:3651-3658.
21. 18F-FDG PET for detection of paraaortic lymph node metastases in cervical cancer patients. J Nucl Med. 2003;44:1775-1783.
22. Mochizuki T, Tsukamoto E, Kuge Y, et al. FDG uptake and glucose transporter subtype expressions in experimental tumor and inflammation models. J Nucl Med. 2001;42:1551-1555.
23. Tabachnick BG, Fidell LS. Using Multivariate Statistics. 4th ed. Boston, MA: Allyn and Bacon; 2001:66-71.
24. Younes M, Brown RW, Stephenson M, Gondo M, Cagle PT. Over expression of Glut1 and Glut3 in stage I non small cell lung cancer is associated with poor survival. Cancer. 1997;80:1046-1051.
25. Kurata T, Oguri T, Isobe T, Ishioka S, Kamakido M. Differential expression of facilitative glucose transporter (GLUT) gene in primary lung cancers and their liver metastases. Jpn J Cancer Res. 1999;99:1123-1143.
26. Mendez LE, Manci N, Cantuaria G, et al. Expression of glucose transporter-1 in cervical cancer and its precursors. Gynecol Oncol. 2002;86:138-143.
27. Brown RS, Leung JY, Fisher SJ, Frey KA, Ethier SP, Wahl RL. Intratumoral distribution of tritiated-FDG in breast carcinoma: correlation between Glut-1 expression and FDG uptake. J Nucl Med. 1996;37:1042-1047.
28. Mathupala SP, Rempel A, Pedersen PL. Aberrant glycolytic metabolism of cancer cells: a remarkable coordination of genetic, transcriptional, post-translational, and mutational events that lead to a critical role for type II hexokinase. J Bioenerg Biomembr. 1997;29:339-343.
29. 18F]fluorodeoxyglucose positron emission tomography imaging in the evaluation of hepatocellular carcinoma. Am Surg. 2003;69:117-124.
30. 3H-2-deoxyglucose retention in murine tumor models. Nucl Med Biol. 1996;23:533-541.
31. Younes M, Lechago LV, Lechago J. Overexpression of the human erythrocyte glucose transporter occurs as a late event in human colorectal carcinogenesis and is associated with an increased incidence of lymph node metastases. Clin Cancer Res. 1996;2:1151-1154.
32. Chang S, Lee S, Lee C, Kim JI, Kim Y. Expression of the human erythrocyte glucose transporter in transitional cell carcinoma of the bladder. Urology. 2000;55:448-452.
33. Cantuaria G, Magalhaes A, Penalver M, et al. Expression of Glut1 glucose transporter in borderline and malignant epithelial tumors of the ovary. Gynecol Oncol. 2000;79:33-37.
34. 18F-FDG PET: histologic and immunohistochemical tissue analysis. J Nucl Med. 2001;42:9-16.
35. Harris AL. Hypoxia: a key regulatory factor in tumor growth. Nat Rev Cancer. 2002;2:38-47.
36. Suzuki M, Kobayashi H, Tanaka Y, et al. Bikunin target genes in ovarian cancer cells identified by microarray analysis. J Biol Chem. 2003;278:14640-14646.